Gyroscope Therapeutics raises $148m in Forbion-led series C
Gyroscope Therapeutics, a London-based clinical-stage gene therapy company, has secured $148m in a series-C financing round led by Forbion’s Growth Opportunities Fund.
More on Early-stage
OpenOcean and Spintop lead €3.6m series-A for Cambri
Lynda Clarizio, former president of Nielsen US Media, joins the board of directors
ByFounders leads $4.6m seed round for Proper
Other investors include PreSeed Ventures, Prehype, Vaekstfonden and Bjarke Ingels
Claris Ventures leads £15.2m series-B for NeoPhore
2Invest, 3B Future Health Fund, Astellas Venture Management and CRT Pioneer Fund also take part in the round
DCVC Bio leads $17m series-A round for BioPhero
Startup will use the funding to start production of its first product and make it available worldwide
Latest News
Essling founder sells business to private investors
Frank-Noël Vandenberghe exits the business he co-founded with Michele Mezzarobba, who left last year
Aurelius raises first fund for institutional investors
Investor's €360m fund has an extra capacity of €150m from the GP's listed vehicle and will focus on carve-outs
Brightlands Venture Partners IV holds €45m first close
Fund invests in renewable chemistry, regenerative medicine and agri-food across the Netherlands, Belgium and parts of Germany
Battery Ventures buys IMC Test & Measurement
Company will operate with the GP's existing test and measurement companies in the US and Denmark